Myocardial extracellular volume

1. SGLT2 inhibitors decrease myocardial extracellular volume in humans (Treatment: 28.3 (1.9)% to 27.3 (1.8)%; control: 26.9 (2.4)% to 27.1 (2.3)%).

   “ECV (SGLT2i: 28.3 (1.9) % to 27.3 (1.8) %, p < 0.001;”

   Human trialHFpEF and diabetes mellitus; added to standard caremyocardium6 months62% malesn = 32

   Myocardial extracellular volume reduction is associated with improved cardiac function after SGLT2 inhibitor therapy in HFpEF

   Scientific reports·Oct 14, 2026

More on SGLT2 inhibitors